KCMF1

KCMF1 is a RING/ZZ-type zinc finger E3 ubiquitin ligase that functions as a central component of the RAD6(E2)–KCMF1–UBR4 ubiquitin ligase complex, directing protein substrates to proteasomal or autophagic degradation through assembly of K48- and K63-linked ubiquitin chains (PMID:25582440, PMID:40992840). Within this complex, KCMF1 serves as a substrate filter: its ZZ domain recognizes Arg/N-degron motifs on stress-modified proteins to promote K63-linked ubiquitination and p62-dependent autophagic clearance, while the UBR4–KCMF1 module extends K48-linked ubiquitin chains on pre-ubiquitinated orphan protein subunits for proteasomal degradation [PMID:40992840, PMID:bio_10.1101_2024.08.07.607117]. KCMF1 also ubiquitinates specific substrates including HRI kinase to suppress the integrated stress response and nucleoredoxin (NXN) to activate β-catenin signaling (PMID:41391693, PMID:41721648). Loss of KCMF1 in vivo prevents pancreatic cancer formation in TGF-α transgenic mice with reduced cyclin D and CDK4 expression, establishing KCMF1 as a promoter of cell proliferation and tumorigenesis (PMID:20473331).

1. 2006 Medium

   The earliest functional link established KCMF1 as a modulator of cell migration downstream of CD99 signaling in Ewing's sarcoma, placing it in a cancer-relevant context before its enzymatic activity was known.

   Evidence RNAi and ectopic overexpression in six ESFT cell lines with migration assays

   PMID:16314831

   Open questions at the time

   • No enzymatic mechanism defined
   • Context-dependent direction of migration effect (suppressor in ESFT vs. promoter in other cancers) not reconciled
2. 2010 Medium

   In vivo genetic evidence demonstrated that KCMF1 is required for pancreatic cancer formation and promotes cell proliferation through cyclin D/CDK4, establishing its oncogenic role beyond migration.

   Evidence KCMF1-knockdown gene trap mice crossed with TGF-α transgenic mice; proliferation/invasion assays; western blot

   PMID:20473331

   Open questions at the time

   • Direct ubiquitin ligase activity not yet shown
   • Mechanism linking KCMF1 to cyclin D/CDK4 expression undefined
3. 2013 Medium

   Identification of 14-3-3σ as a physical interactor in colon cancer stem cells suggested KCMF1 participates in signaling scaffolds controlling proliferation, though the biochemical consequence of this interaction remained unclear.

   Evidence Yeast two-hybrid screening and co-immunoprecipitation with knockdown proliferation assays

   PMID:23840115

   Open questions at the time

   • Whether KCMF1 ubiquitinates 14-3-3σ not tested
   • No reciprocal validation beyond Co-IP
4. 2015 High

   The molecular architecture of KCMF1 as an E3 ligase was resolved: its C-terminus directly binds the E2 enzyme RAD6 and its N-terminus binds UBR4, forming a defined E2–E3 complex that localizes to late endosomes/lysosomes and whose disruption impairs vesicle dynamics.

   Evidence AP-MS, NMR direct binding, co-localization imaging, and functional assays; RAD6 disease-associated point mutants lose KCMF1 binding

   PMID:25582440

   Open questions at the time

   • Physiological substrates of the RAD6–KCMF1–UBR4 complex not identified
   • Ubiquitin chain type assembled by the complex not determined
5. 2024 High

   Cryo-EM and reconstitution studies revealed UBR4–KCMF1 forms a ~1.3 MDa ring structure where KCMF1 acts as a substrate filter, and the complex degrades orphan protein subunits via a two-step mechanism requiring priming mono-ubiquitination followed by K48-linked chain extension.

   Evidence Cryo-EM of UBR4–KCMF1–CALM1 complex (preprint); genetic epistasis and in vitro reconstitution (preprint); TRIM52 as validated substrate with BIRC6 as priming E3 (preprint)

   PMID:bio_10.1101_2024.05.16.594269 PMID:bio_10.1101_2024.08.07.607117 PMID:bio_10.1101_2024.12.18.629163

   Open questions at the time

   • Structural studies are preprints awaiting peer review
   • Full range of orphan substrates recognized not catalogued
   • How KCMF1 filters substrates at the structural level remains partially resolved
6. 2025 High

   The dual degradation pathways mediated by KCMF1 were mechanistically defined: its ZZ domain recognizes Arg/N-degrons on oxidatively modified Cys2 residues to assemble K63-linked chains for autophagic clearance, while substrate-specific ubiquitination of HRI suppresses the integrated stress response.

   Evidence In vitro reconstitution with synthetic N-degrons and ubiquitination assays; Ni-NTA pull-down ubiquitination and knockdown/overexpression with xenograft model

   PMID:40992840 PMID:41391693

   Open questions at the time

   • Whether K63 vs K48 chain assembly is determined by substrate or by complex composition is unresolved
   • Physiological importance of KCMF1-mediated HRI degradation in non-cancer contexts unknown
7. 2025 Medium

   Beyond canonical ubiquitin ligase activity, KCMF1 was shown to interact with FUS and promote its nuclear translocation, and to ubiquitinate NXN for K63-linked degradation activating β-catenin signaling, broadening the substrate and pathway repertoire.

   Evidence Co-IP and functional studies for FUS interaction; IP-MS, co-IP, and ubiquitination assays for NXN

   PMID:41184988 PMID:41721648

   Open questions at the time

   • FUS interaction identified by single Co-IP without reciprocal validation
   • Whether KCMF1–FUS interaction involves ubiquitination of FUS not tested
   • K63-linked ubiquitination of NXN leading to degradation rather than signaling modification not fully distinguished

• Key open questions include how KCMF1 switches between K48- and K63-linked chain assembly, the full physiological substrate landscape of the UBR4–KCMF1 complex, and how KCMF1's catalytic versus scaffolding roles are coordinated in different cellular compartments.
• No systematic substrate profiling across tissues
• Structural basis for chain-type selectivity not determined
• Relative contribution of proteasomal vs autophagic degradation branches in vivo unknown